Page 4 - Pharmaceuticals Stock News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Pharmaceuticals stock. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Pharmaceuticals Stock Today - Breaking & Trending Today

ORIC Pharmaceuticals (NASDAQ:ORIC) Trading Up 6.5%

ORIC Pharmaceuticals (NASDAQ:ORIC) Trading Up 6.5%
theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.

United States , Oric Pharmaceuticals Inc , Cantor Fitzgerald , Pharmaceuticals Daily , Algert Global , Alkeon Capital Management , Pharmaceuticals Company Profile , Euclidean Capital , Pharmaceuticals Stock , Vivo Capital , Jpmorgan Chase Co , Jump Financial , Pharmaceuticals Inc , Get Free Report , Capital Management ,

ACADIA Pharmaceuticals (NASDAQ:ACAD) Receives Overweight Rating from Cantor Fitzgerald

ACADIA Pharmaceuticals (NASDAQ:ACAD – Get Free Report)‘s stock had its “overweight” rating reaffirmed by investment analysts at Cantor Fitzgerald in a research report issued to clients and investors on Tuesday, Benzinga reports. They currently have a $37.00 price target on the biopharmaceutical company’s stock. Cantor Fitzgerald’s target price indicates a potential upside of 117.01% from […] ....

United States , Brendan Teehan , Zurcher Kantonalbank Zurich Cantonalbank , Stephen Davis , Raymond James Associates , Pharmaceuticals Inc , Needham Company , Pharmaceuticals Stock , Emerald Mutual Fund Advisers , Cantor Fitzgerald , Acadia Pharmaceuticals , Pharmaceuticals Daily , Emerald Advisers , Mirae Asset Global Investments Co , Securities Exchange Commission , Get Free Report , Exchange Commission , Kantonalbank Zurich Cantonalbank , Asset Global Investments , Emerald Mutual Fund Advisers Trust , Mutual Fund Advisers Trust , Nasdaq Acad , Reiterated Rating ,

Brookline Capital Management Equities Analysts Increase Earnings Estimates for X4 Pharmaceuticals, Inc. (NASDAQ:XFOR)

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR – Free Report) – Equities research analysts at Brookline Capital Management increased their FY2026 earnings estimates for X4 Pharmaceuticals in a research report issued to clients and investors on Monday, April 29th. Brookline Capital Management analyst L. Cann now expects that the company will earn $0.32 per share for the year, […] ....

Adams Mostafa , Barclays Plc , Sg Americas Securities , Securities Exchange Commission , Pharmaceuticals Stock , Pharmaceuticals Inc , Pharmaceuticals Daily , Capital Partners , Stonepine Capital Management , Free Report , Brookline Capital Management , Capital Management , Get Free Report , Exchange Commission , X4 Pharmaceuticals , Nasdaq Xfor , Earnings Estimates ,

Insider Selling: ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Insider Sells $928,000.00 in Stock

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY – Get Free Report) insider Sarina Tanimoto sold 100,000 shares of the firm’s stock in a transaction dated Tuesday, April 16th. The shares were sold at an average price of $9.28, for a total transaction of $928,000.00. Following the transaction, the insider now directly owns 1,647,447 shares in the company, valued […] ....

Sarina Tanimoto , William Blair , Leerink Partnrs , Geode Capital Management , Ars Pharmaceuticals Inc , Squarepoint Ops , Pharmaceuticals Daily , Pharmaceuticals Stock , Ameriprise Financial Inc , Pharmaceuticals Inc , Get Free Report , Capital Management , Street Corp , Street Group , Ameriprise Financial , Ars Pharmaceuticals , Nasdaq Spry , Insider Trading , Nsider Trades ,

TRACON Pharmaceuticals (NASDAQ:TCON) Coverage Initiated by Analysts at StockNews.com

Analysts at StockNews.com assumed coverage on shares of TRACON Pharmaceuticals (NASDAQ:TCON – Get Free Report) in a report released on Tuesday. The brokerage set a “strong-buy” rating on the biopharmaceutical company’s stock. Separately, HC Wainwright lowered their price objective on shares of TRACON Pharmaceuticals from $120.00 to $60.00 and set a “buy” rating on the […] ....

United States , Renaissance Technologies , York Mellon Corp , Pharmaceuticals Company Profile , Pharmaceuticals Inc , Pharmaceuticals Daily , Pharmaceuticals Stock , Virtu Financial , Millennium Management , Ci Private Wealth , Get Free Report , New York Mellon Corp ,